Winstrol (Stanozolol)

Anabolic steroid users usually start first with oral preparations. Examples of commonly used oral anabolic steroid preparations include Anavar, Winstrol, Dianabol, Halotestin, and Adroyd. In addition to the 17-alpha modification, oral anabolic steroids may have been modified at one or more molecular sites. Winstrol (Stanozolol) has a molecular alteration that causes a steric hindrance that makes it non-aromatizable via enzymes to estrogens. Most of these additional modifications enhance the activity of the steroid to promote the anabolic over androgenic functions, thus altering the steroids’ Therapeutic Index. Winstrol (originally manufactured by Winthrop) has a Therapeutic Index of 5-20.

Testosterone and Stanozolol (brand name Winstrol) are examples of anabolic steroids available in water-based preparations. Winstrol is an example of an aqueous anabolic steroid manufactured by pharmaceutical companies for veterinary use. It comes in 10, 30, and 50 milliliter vials with a concentration of 50 mg/cc. This concentrated dose (2mg is the concentration for oral human use) is intended for large animals.

Most anabolic steroids contain active ingredients in a liquid solution. This solution consists of either oil or water; hence, the self explanatory terms “oil-based” and “water-based”. These two subtypes, in turn, differ in their characteristics and effects. All water-based anabolics are fast-acting and short-lasting. Anabolics such as Winstrol, for example, reportedly exert an effect within 1-2 hours, but are active only for 1 or 2 days. This necessitates more frequent use. Winstrol is often used every other day. Oil-based anabolics can either have a short half-life within the body or exert a prolonged biological effect. 

Winstrol Use in Fighting Osteoporosis

CST-induced osteoporosis is the most dangerous and “brittle” type of osteoporosis. As anabolic steroids became available for clinical use in the late 1950s, they were shown to be an effective treatment for preventing and reversing the catabolic bone effects brought on by prolonged and concurrent corticosteroid therapy in patients with rheumatoid arthritis in both men and women. The chronological listing of some of the major events regarding the history of anabolic steroid therapy for CST-induced osteoporosis shows that Winthrop Laboratories published its packaged insert for the anabolic steroid, Winstrol (Stanozolol), indicating that it could be used to treat for CST-induced osteoporosis. Anabolic steroid therapy should be considered for not only prevention, but the treatment of CST-induced osteoporosis on a case-by-case basis. Due to the continued post-treatment stimulation of bone mass, one should consider a cyclical regimen, especially for women patients. In clinical studies, prescribing 2 to 4 mg of Winstrol (Stanozolol) daily for 10 to 14 days consecutively each month to CST-induced osteoporosis women patients has reversed bone loss.


Recent studies have reopened the concept of prescribing anabolic steroids in men with osteoporosis. As a result, anabolic steroid therapy should be viewed as an appropriate therapy in treating osteoporosis in men. Clinical experience shows that one of the best treatments utilizes a cyclical Winstrol (Stanozolol) regimen of 10 mg daily for 2-3 weeks each month. When male patients are treated with this regimen, bone density increases without any unwanted adverse effects.

Winstrol As an Anabolic

Winstrol is used due to its unique characteristics as an anabolic steroid. First, it has one of the highest anabolic-to-androgenic (Therapeutic Index) ratios of all the androgens. This high Therapeutic Index (5-20) significantly reduces any virilization potentials. Second, because of its bio-chemical structure, Winstrol is not aromatized to estrogens that further reduce any adverse effects due to the excess of estrogens. Third, Winstrol has been shown to directly stimulate osteoblast activity and produce an increased normal bone mineral density. Fourth, Winstrol possesses an action that may reduce the potential of abnormal blood clots that can be an adverse effect of estrogen therapy. Finally, Winstrol prescribed in small doses for 10 days each month mimics the 10-day testosterone elevation produced by the normally functioning ovaries as stimulated by the pituitary’s spike in luteinizing hormone (LH) release.

Winstrol for Treating Raynaud’s Syndrome

There have been a number of medications used for the treatment and clinical management of Raynaud’s Syndrome (RS). However, for severe RS, the anabolic steroid Winstrol (Stanozolol) has been used with significant results. Prior to the early 1980s, Winstrol was approved by the FDA for use in irretractable Raynaud’s Syndrome. Winstrol therapy reduces plasma Fibrinogen levels and thus has been of important value in the treatment of patients with severe RS. Winstrol therapy may also be of benefit in alleviating or reducing many symptoms associated with the underlying immunologic diseases and RS, such as muscle wasting, immunologic compromise, osteoporosis, mental depression, loss of libido, and reduced general well-being.

Other Names for Winstrol

Stromba (Greece); Menabol, Neurabol (India); Winstrol (Spain, USA), Cetabon (Thailand)


Copyright © 2015 - All Rights Reserved.
20-22 Wenlock Road, London, N1 7GU, England

Mobile Site